ME Therapeutics Holdings Management
Management criteria checks 0/4
ME Therapeutics Holdings' CEO is Salim Dhanji, appointed in Mar 2023, has a tenure of 1.75 years. directly owns 17.67% of the company’s shares, worth CA$12.53M. The average tenure of the management team and the board of directors is 1.8 years and 1.8 years respectively.
Key information
Salim Dhanji
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.8yrs |
| CEO ownership | 17.7% |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO
Salim Dhanji
1.8yrs
Tenure
Dr. Salim Dhanji is Chief Executive Officer and Director of ME Therapeutics Holdings Inc. from March 9, 2023. He serves as Head of Pre-Clinical Research at Qu Biologics Inc. Dr. Dhanji has done extensive p...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | no data | 17.67% CA$ 12.5m | |
| Chief Financial Officer | 1.8yrs | CA$47.83k | no data | |
| Corporate Secretary | 1.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
1.8yrs
Average Tenure
Experienced Management: METX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | no data | 17.67% CA$ 12.5m | |
| Director | 1.8yrs | no data | 17.64% CA$ 12.5m | |
| Director | 1.5yrs | no data | no data | |
| Director | 1.8yrs | no data | 17.67% CA$ 12.5m |
1.8yrs
Average Tenure
Experienced Board: METX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 13:06 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ME Therapeutics Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|